US Pharma Investment: GSK’s $30 Billion Commitment to Growth
US Pharma Investment is rapidly changing the landscape of the pharmaceutical industry, as leading companies shift their focus to the United States for growth opportunities.Recent commentary from GSK’s CEO, Dame Emma Walmsley, underscores the shift, revealing plans for a staggering $30 billion investment in the US by 2030.










